Abstract
From 2014 to May 2015, >26 000 Ebola virus disease (EVD) cases were reported from West Africa. We present a patient with EVD who received brincidofovir and convalescent plasma. The relative contributions of supportive care, investigational therapies, and patient's immune-response on survival could not be determined. Randomized trials are needed.
Keywords:
Ebola; investigational therapies; trials.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: [email protected].
MeSH terms
-
Adult
-
Africa, Western
-
Alanine Transaminase / blood
-
Antibodies, Viral / blood
-
Antiviral Agents / administration & dosage*
-
Aspartate Aminotransferases / blood
-
Bilirubin / blood
-
Cytosine / administration & dosage
-
Cytosine / analogs & derivatives*
-
Hemorrhagic Fever, Ebola / therapy*
-
Humans
-
Immunization, Passive*
-
Immunoglobulin G / blood
-
Immunoglobulin M / blood
-
Leukocyte Count
-
Male
-
Organophosphonates / administration & dosage*
-
Plasma*
-
Platelet Count
-
RNA, Viral / blood
-
Randomized Controlled Trials as Topic
-
Treatment Outcome
-
Viral Load
Substances
-
Antibodies, Viral
-
Antiviral Agents
-
Immunoglobulin G
-
Immunoglobulin M
-
Organophosphonates
-
RNA, Viral
-
brincidofovir
-
Cytosine
-
Aspartate Aminotransferases
-
Alanine Transaminase
-
Bilirubin